{
    "clinical_study": {
        "@rank": "80578", 
        "arm_group": [
            {
                "arm_group_label": "lean (BMI\u2264 24.9 Kg/m2)", 
                "description": "9 lean (BMI\u2264 24.9 Kg/m2)"
            }, 
            {
                "arm_group_label": "obese (BMI= 30-40 Kg/m2)", 
                "description": "9 obese (BMI= 30-40 Kg/m2)"
            }, 
            {
                "arm_group_label": "psoriatic lean", 
                "description": "9 psoriatic lean"
            }, 
            {
                "arm_group_label": "psoriatic obese", 
                "description": "9 psoriatic obese"
            }
        ], 
        "biospec_descr": {
            "textblock": "Fat Biopsy"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and\n      risk factor for type 2 diabetes and the metabolic syndrome. It is also often linked to\n      cardiovascular disease, certain cancers (e.g., colorectal, esophageal, endometrial, and\n      ovarian), and inflammatory diseases (e.g., psoriasis, osteoarthritis,inflammatory bowel\n      disease).The phenotyping of subcutaneous adipose tissue (SAT) hematopoetic cells from obese\n      subjects by flow cytometry, microscopy and gene expression will enable us  to identify\n      inflammation in this tissue and may help us to understand the causes and consequences of\n      obesity in order to determine how these cells might be implicated in the initiation and/or\n      progression of the aforementioned diseases."
        }, 
        "brief_title": "A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Psoriasis", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Psoriasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and\n      risk factor for type 2 diabetes and the metabolic syndrome. It is also often linked to\n      cardiovascular disease, certain cancers (e.g., colorectal, esophageal, endometrial, and\n      ovarian), and inflammatory diseases (e.g., psoriasis, osteoarthritis,inflammatory bowel\n      disease).The phenotyping of subcutaneous adipose tissue (SAT) hematopoetic cells from obese\n      subjects by flow cytometry, microscopy and gene expression will enable us  to identify\n      inflammation in this tissue and may help us to understand the causes and consequences of\n      obesity in order to determine how these cells might be implicated in the initiation and/or\n      progression of the aforementioned diseases."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Psoriatic lean cohort (BMI between 18-24.9 Kg/m2): moderate to severe plaque-type, at\n             least 5% of BSA\n\n          -  Psoriatic obese cohort (BMI between 30-40 Kg/m2): moderate to severe plaque-type, at\n             least 5% of BSA\n\n          -  Lean/non-psoriatic cohort: BMI between 18-24.9 Kg/m2\n\n          -  Overweight/obese non-psoriatic cohort: BMI between 30-40 Kg/m2\n\n          -  Subjects must be 18-65 years of age\n\n        Exclusion Criteria:\n\n          -  Having received any systemic treatment for psoriasis within the last 30 days\n\n          -  history of bleeding disorder\n\n          -  weight loss of 10 pounds in the last four weeks\n\n          -  current smoker\n\n          -  Known diagnosis of any unrelated autoimmune disease or inflammatory disease ( i.e.\n             lupus, atopic dermatitis, rheumatoid arthritis).\n\n          -  Currently taking NSAIDS, aspirin, (if > once a week, stopped <30 days ago). Aspirin\n             81mg may be permitted if the Framingham Risk Score is < 10\n\n          -  Having received any anti-inflammatory medication within the last 30 days\n\n          -  Current use of any anti-coagulants\n\n          -  LFTs > 2 x upper normal limits\n\n          -  HIV infection\n\n          -  Pregnant\n\n          -  Less than 6 weeks post partum\n\n          -  history of cardiovascular disease (MI, CHF, CVA)\n\n          -  Any cancer diagnosis within the last 5 years\n\n          -  Symptoms of acute illness such as upper respiratory infection, bronchitis,\n             gastroenteritis, or fever within 3 days of Visit 1\n\n          -  Any medical, psychological or social condition that, in the opinion of the\n             Investigator, would jeopardize the health or well-being of the participant during any\n             study procedures or the integrity of the data\n\n          -  ingestion of DHA or fish oil within last 90 days\n\n          -  hypertension as defined as > 140 systolic and > 90 diastolic after 10  minutes of\n             resting on 2 antihypertensives\n\n          -  Use of statins within the last 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Obesity and psoriasis are characterized by infiltration of inflammatory cells (leukocytes)\n        in SAT and skin, respectively.  We expect that SAT in obese psoriasis subjects will have\n        infiltrating inflammatory leukocytes because of obesity, and that these  infiltrating\n        leukocytes might be different and/or increased in numbers  by the pathology of psoriasis"
            }
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856647", 
            "org_study_id": "JUG-0799"
        }, 
        "intervention": {
            "arm_group_label": [
                "lean (BMI\u2264 24.9 Kg/m2)", 
                "obese (BMI= 30-40 Kg/m2)", 
                "psoriatic lean", 
                "psoriatic obese"
            ], 
            "description": "An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.", 
            "intervention_name": "Adipose tissue biopsy (fat biopsy)", 
            "intervention_type": "Procedure", 
            "other_name": "Adipose tissue biopsy (fat biopsy)"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy Volunteers", 
            "Psoriasis", 
            "Obesity"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "contact": {
                "last_name": "Lauren Corregano"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "The Rockefeller University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)", 
        "overall_contact": {
            "email": "rucares@rockefeller.edu", 
            "last_name": "Tyler Rainer", 
            "phone": "1-800-RU-CARES"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Biomarkers for phenotyping a new type of leukocyte", 
            "measure": "Biomarkers for phenotyping a new type of leukocyte", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rockefeller University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rockefeller University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}